AstraZeneca and California-based Forty Seven initiated a new triple combination therapy clinical trial has the potential to create additional opportunities to further optimize treatment for patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma (NHL).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,